

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
CLINICAL TRIAL AUTHORIZATION FOR INITIATING
A PHASE III CLINICAL TRIAL OF OT-802 ACCEPTED IN CHINA

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that a phase III clinical trial authorization for initiating a randomized, double-masked, placebo-controlled, parallel-group, multi-center clinical trial for OT-802 (pilocarpine hydrochloride), a self-developed product of the Group targeting the indication of presbyopia, has recently been accepted by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (the “**PRC**”). The presbyopia treatment market presents significant commercial potential, particularly in the PRC where no pharmaceutical treatment has been approved for commercial use to date. The authorization for initiating the phase III clinical trial of OT-802 demonstrates the research and development capabilities of the Group and highlights the considerable potential in the currently underserved presbyopia treatment market.

OT-802, namely pilocarpine hydrochloride, is an innovative product independently developed by the Company for the treatment of presbyopia. According to preclinical studies, OT-802 demonstrates characteristics of rapid onset and a favorable safety profile. The Group applied the same dual-chamber liquid-liquid formulation technology used in OT-101 (0.01% atropine sulfate eye drop) to OT-802, effectively addressing product stability challenges. The Group possesses exclusive patent rights for this proprietary technology and will commence the phase III clinical trial of OT-802 as soon as possible.

Cautionary Statement: The Company cannot guarantee that that it will develop and ultimately commercialize OT-802 (pilocarpine hydrochloride) successfully. **Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 10, 2025

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.